Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|December 13, 2016
Aligning the Needs of Specialty Pharmacies and Manufacturers
Author(s)Laurie Toich, Assistant Editor
John Campo, vice president of Pharmacy Trade Relations and Contracting at Managed Health Care Associates discusses how to improve the relationship between specialty pharmacies and specialty drug manufacturers.
Advertisement
John Campo, vice president of Pharmacy Trade Relations and Contracting at Managed Health Care Associates discusses how to improve the relationship between specialty pharmacies and specialty drug manufacturers.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5